Comparative Pharmacology
Head-to-head clinical analysis: AMNESTEEM versus FABIOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMNESTEEM versus FABIOR.
AMNESTEEM vs FABIOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoid that binds to and activates retinoic acid receptors (RARs), thereby normalizing keratinocyte differentiation and reducing sebum production.
Retinoid that binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), inducing differentiation and apoptosis of keratinocytes.
0.5-1.0 mg/kg/day orally in 2 divided doses
FABIOR (tazarotene) foam, 0.1%: Apply a thin layer once daily in the evening to affected areas of the face, scalp, or trunk.
None Documented
None Documented
Terminal elimination half-life: 10-20 hours (mean 17 hours) in patients with normal renal function; prolonged in severe renal impairment
Terminal elimination half-life is approximately 24-26 hours, supporting once-daily dosing.
Renal (65-83% as unchanged drug and metabolites), fecal (15-35% as metabolites)
Primarily hepatic metabolism via CYP450; renal excretion of metabolites accounts for <1% of dose as unchanged drug. Fecal elimination is the major route (approximately 90%).
Category C
Category C
Retinoid
Retinoid